Skip to main content
padlock icon - secure page this page is secure

Ganciclovir: Antiviral Therapy for Congenital Cytomegalovirus

Buy Article:

$17.00 + tax (Refund Policy)

CYTOMEGALOVIRUS (CMV), a member of the herpesvirus family, is the most common virus passed from the mother to the fetus. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 150 children is born with congenital CMV infection.1 Neonates may also acquire CMV during delivery, via blood transfusions, or through breast milk. Both prenatally and perinatally infected infants are at risk for developing short-term effects and long-term sequelae and are candidates for antiviral therapy.2 Each year, approximately 8,000 children suffer permanent disabilities secondary to CMV infection.1

No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: January 1, 2009

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more